AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
Ente Ospedaliero Cantonale, Bellinzona
140 participants
Sep 1, 2024
INTERVENTIONAL
Conditions
Summary
Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. The primary objective of this study is to determine if adding AI-assisted migraine education to standard education improves patients' understanding of their condition more effectively.
Eligibility
Inclusion Criteria4
- aged between 18 and 65 years at the time of signing the informed consent
- Newly diagnosis of migraine, confirmed through the medical chart
- The participant must be capable of giving signed informed consent
- Access to a laptop, computer, smartphone, or tablet
Exclusion Criteria3
- Insufficient knowledge of the protocol language (italian)
- Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study.
- Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
AIME Group will undergo the established migraine education plus AI-assisted education.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06507150